145733-36-4

145733-36-4 structure

Name: Tasosartan
Chemical Name: 2,4-dimethyl-8-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6-dihydropyrido[2,3-d]pyrimidin-7-one
CAS Number: 145733-36-4
Molecular Formula: C₂₃H₂₁N₇O
Molecular Weight: 411.459
Catalog: Signaling Pathways GPCR/G Protein Angiotensin Receptor
Create Date: 2018-08-29 19:18:36
Modify Date: 2025-08-25 23:37:59
Tasosartan is a long-acting angiotensin II (AngII) receptor antagonist.

Name	2,4-dimethyl-8-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6-dihydropyrido[2,3-d]pyrimidin-7-one
Synonyms	2,4-dimethyl-8-{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one ANA-756 2,4-Dimethyl-8-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one Pyrido[2,3-d]pyrimidin-7(6H)-one, 5,8-dihydro-2,4-dimethyl-8-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- 2,4-Dimethyl-8-{[2'-(1H-tetrazol-5-yl)-4-biphenylyl]methyl}-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one 2,4-dimethyl-5,6,8-trihydro-8-[[2'-(1H-tetrazol-5-yl)[1,1-biphenyl]-4-yl]methyl]-7H-pyrido[2,3-d]pyrimidin-7-one 2,4-dimethyl-8-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one 8-[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl-methyl]-2,4-dimethyl-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one Tasosartan (USAN/INN) WAY-ANA-756 S1539_Selleck Verdia tasosartan

Description	Tasosartan is a long-acting angiotensin II (AngII) receptor antagonist.
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Angiotensin Receptor Research Areas >> Cardiovascular Disease
Target	Angiotensin II (AngII) receptor[1]
In Vitro	Tasosartan is an orally active nonpeptide AngII antagonist that has demonstrates specific and selective AT1 receptor antagonistic activity in vitro. IC50 for inhibition of specific binding of 125I-AngII to rat adrenal membrane in the absence of proteins in binding buffer is 1.2±0.6 nM[1].
In Vivo	Administration of Tasosartan at doses of 1.0 and 3.0 mg/kg (iv) significantly (p<0.05) attenuates the pressor response to angiotensin-II in rats[2].
Animal Admin	Rats[2] Pressor response to angiotensin-II administration in four groups of rats (n=3-5 each, weighing 343±8 g). Each rat is subjected to four separate bolus injections of angiotensin-II following the introduction of either the vehicle or graded doses of Tasosartan (0.3, 1.0, or 3.0 mg/kg, iv)[2].
References	[1]. Maillard MP, et al. Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000 Nov;295(2):649-54. [2]. Elokdah HM, et al. Novel human metabolites of the angiotensin-II antagonist Tasosartan and their pharmacological effects. Bioorg Med Chem Lett. 2002 Aug 5;12(15):1967-71.

149049-80-9

~39%

145733-36-4

Literature: American Home Products Corporation Patent: US5149699 A1, 1992 ; US 5149699 A

153042-17-2

~73%

145733-36-4

1501-06-0

145733-36-4

Literature: Journal of Medicinal Chemistry, , vol. 37, # 4 p. 542 - 550

22814-39-7

145733-36-4

Literature: Journal of Medicinal Chemistry, , vol. 37, # 4 p. 542 - 550

22814-29-5

145733-36-4

Literature: Journal of Medicinal Chemistry, , vol. 37, # 4 p. 542 - 550

145733-62-6

145733-36-4

Literature: Journal of Medicinal Chemistry, , vol. 37, # 4 p. 542 - 550

Precursor 3
1501-06-0 22814-29-5 145733-62-6
DownStream 0